Publication: Andrographolide Reduces Lipid Droplet Accumulation in Adipocytes Derived from Human Bone Marrow Mesenchymal Stem Cells by Suppressing Regulators of Adipogenesis
Issued Date
2021-08-18
Resource Type
ISSN
15205118
00218561
00218561
Other identifier(s)
2-s2.0-85114030187
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Agricultural and Food Chemistry. Vol.69, No.32 (2021), 9259-9269
Suggested Citation
Mintra Kaewkittikhun, Nittaya Boonmuen, Pakpoom Kheolamai, Sirikul Manochantr, Chairat Tantrawatpan, Nareerat Sutjarit, Duangrat Tantikanlayaporn Andrographolide Reduces Lipid Droplet Accumulation in Adipocytes Derived from Human Bone Marrow Mesenchymal Stem Cells by Suppressing Regulators of Adipogenesis. Journal of Agricultural and Food Chemistry. Vol.69, No.32 (2021), 9259-9269. doi:10.1021/acs.jafc.1c02724 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/75601
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Andrographolide Reduces Lipid Droplet Accumulation in Adipocytes Derived from Human Bone Marrow Mesenchymal Stem Cells by Suppressing Regulators of Adipogenesis
Abstract
Obesity has become a major public health concern; so, a strategy to prevent or reduce obesity is a priority. The inhibition of lipid droplet accumulation and adipogenesis process provides a target for the treatment of obesity. Herein, the effect of andrographolide (AP) on lipid accumulation in adipocytes derived from human bone marrow mesenchymal stem cells (hBM-MSCs) was examined. AP at concentrations of 1, 2.5, 5, and 10 μM reduced lipid droplet accumulation in the adipocytes by suppressing the adipogenic differentiation of hBM-MSCs. Concurrently, the expressions of adipogenic marker genes and the level of adipokines secreted by adipocytes were suppressed. Gene screening analysis showed a negative regulation of genes involved in the adipogenesis process. In conclusion, we demonstrated for the first time an antilipid accumulation in adipocytes from hBM-MSCs by AP. The compound may potentially be a novel therapeutic agent for the treatment of obesity as well as obesity-related diseases.